查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1870275

BREO Ellipta 製药市场按作用机制、适应症和最终用户划分 - 全球预测 2025-2032

BREO Ellipta Drugs Market by Mechanism Of Action, Indication, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，BREO Ellipta 製药市场将成长至 45.9 亿美元，复合年增长率为 4.68%。

关键市场统计数据
基准年 2024 31.8亿美元
预计年份：2025年 33.3亿美元
预测年份 2032 45.9亿美元
复合年增长率 (%) 4.68%

透过概述 BREO Ellipta 疗法的药理学、实际效用以及在设备和依从性方面的差异优势，将 BREO Ellipta 疗法策略性地应用于临床实践。

本执行摘要概述了 BREO Ellipta 疗法在现代呼吸照护中的临床概况和策略意义。

呼吸系统护理路径的演变由个人化指南、数位化依从性技术、供应链韧性和永续性优先事项所驱动。

不断发展的指南、技术的应用以及对以患者为中心的护理路径的重新关注，正在推动呼吸护理领域发生变革性转变。

评估2025年关税变化对吸入疗法药品采购、在地化生产、价格谈判和供应韧性的影响

2025 年美国实施的关税政策变化的累积影响将对吸入疗法的药品供应链、定价策略和商业性执行产生重大影响。

全面的細項分析揭示了作用机制、临床适应症多样性和终端用户护理环境如何决定产品采纳路径和商业策略。

关键的細項分析洞察揭示了治疗机制、临床适应症和实践环境如何共同影响采用趋势和商业性优先事项。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 真实世界数据支持 BREO Ellipta 在不同患者群体中降低 COPD 急性恶化的有效性，从而推动了该产品的应用。
  • 随着GINA气喘指引的修订，BREO Ellipta作为第一线维持治疗药物的处方行为正在转变。
  • 针对嗜酸性粒细胞细胞表型的新兴生物製药的市场阻力正在影响Ellipta的处方率。
  • 来自生物相似吸入型皮质类固醇组合药物的价格压力对 BREO Ellipta 的市占率成长构成挑战
  • 扩大患者援助计划有助于降低 BREO Ellipta 的价格，并鼓励保险不足的人群更多地使用该药物。
  • 数位吸入器附加元件组件集成，以改善远端疾病管理中 BREO Ellipta 患者依从性监测
  • 三联疗法吸入器的竞争定位降低了 BREO Ellipta 在重度 COPD 领域的市场差异化优势。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. BREO Ellipta 製药市场依作用机制划分

  • ICS
  • ICS/LABA
    • Fluticasone替卡松/Vilanterol
  • ICS/LAMA/LABA
    • Fluticasone替卡松、乌美溴铵和Vilanterol
  • LABA
  • LAMA
    • 乌美克利丁
  • LAMA/LABA
    • 乌美溴铵/Vilanterol

9. BREO Ellipta 製药市场依适应症划分

  • 气喘
  • 气喘及慢性阻塞性肺病并存
  • COPD

第十章 BREO Ellipta 製药市场（依最终用户划分）

  • 居家医疗
  • 医院
  • 专科诊所

第十一章：BREO Ellipta製药市场区域划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章 BREO Ellipta製药市场（依集团划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章：BREO Ellipta製药市场（依国家划分）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • GlaxoSmithKline plc
    • AstraZeneca plc
    • Boehringer Ingelheim International GmbH
    • Novartis AG
    • Chiesi Farmaceutici SpA
    • Teva Pharmaceutical Industries Ltd
    • Viatris Inc.
    • Cipla Ltd
    • Sun Pharmaceutical Industries Ltd
    • Lupin Limited
Product Code: MRR-81515600A1FD

The BREO Ellipta Drugs Market is projected to grow by USD 4.59 billion at a CAGR of 4.68% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.18 billion
Estimated Year [2025] USD 3.33 billion
Forecast Year [2032] USD 4.59 billion
CAGR (%) 4.68%

A strategic introduction that situates BREO Ellipta therapies within clinical practice by outlining pharmacology, real-world utility, and differentiating device and adherence advantages

This executive introduction frames the clinical profile and strategic significance of BREO Ellipta therapies within contemporary respiratory medicine.

BREO Ellipta, a once-daily fixed-dose inhaled combination, integrates an inhaled corticosteroid with a long-acting beta2-agonist to deliver convenient, adherence-friendly therapy for airway inflammatory disease. Clinically, the formulation targets both maintenance therapy for asthma and the chronic management of COPD where anti-inflammatory control and bronchodilation are central to symptom reduction and exacerbation prevention. The dry powder inhaler device platform supports standardized dosing, ease of use for many patients, and compatibility with patient education programs designed to improve long-term adherence.

From a strategic lens, this product class occupies an intersection of established pharmacology and evolving therapeutic expectations. Payers and providers increasingly evaluate therapies on their real-world effectiveness, safety profile, and capacity to reduce acute care utilization. Consequently, clinical differentiators such as dosing frequency, inhaler ergonomics, and the robustness of post-marketing safety data materially shape clinician prescribing behavior and formulary positioning. Furthermore, lifecycle management opportunities-ranging from label expansions to device enhancements-remain central to sustaining therapeutic relevance amidst intensifying competition and shifting care models.

Evolving respiratory care pathways driven by guideline personalization, digital adherence technologies, supply chain resilience, and sustainability priorities

The respiratory landscape is undergoing transformative shifts driven by guideline evolution, technology adoption, and a renewed focus on patient-centric care pathways.

Guideline updates increasingly emphasize personalized approaches that match inhaled controller intensity to individual risk profiles, spurring greater interest in both dual and triple combination regimens for patients whose symptoms and exacerbation history justify escalated therapy. At the same time, technological innovation-ranging from connected inhaler sensors to telehealth-enabled adherence programs-has changed how clinicians monitor and support patients, enabling more proactive interventions and data-driven treatment optimization. These digital adjuncts also create new value propositions for therapeutics, linking pharmacologic effect with measurable improvements in daily inhaler use.

Supply chain resilience and environmental considerations are reshaping procurement and formulary choices. Manufacturers and healthcare systems are prioritizing sourcing strategies that mitigate disruption risk while also responding to institutional sustainability targets. In parallel, payers are intensifying scrutiny of long-term outcomes and total cost of care, encouraging manufacturers to demonstrate not only clinical efficacy but also economic value in real-world settings. As a result, successful products increasingly combine clinical excellence with pragmatic delivery and commercial strategies that align with evolving healthcare priorities.

Assessing how 2025 tariff changes reshape pharmaceutical sourcing, manufacturing localization, pricing negotiations, and supply resilience for inhaled therapies

The cumulative impact of tariff policy shifts implemented in the United States in 2025 has important implications for pharmaceutical supply chains, pricing strategies, and commercial execution for inhaled therapies.

Tariff adjustments that affect imported pharmaceutical ingredients, device components, and packaging materials introduce added cost volatility and compel manufacturers to reassess sourcing strategies. In response, companies are accelerating localization of key manufacturing steps, diversifying supplier portfolios, and renegotiating long-term contracts to insulate margins and maintain predictable supply. These operational changes, in turn, influence inventory planning and the cadence of product launches in affected markets. For manufacturers that rely on cross-border supply chains for active pharmaceutical ingredients or specialized inhaler components, the need for contingency planning has become a front-line commercial priority.

Beyond manufacturing, tariff-driven cost pressures can reshape pricing and reimbursement negotiations. Payers and providers may-expect greater transparency on cost drivers and may push for value-based arrangements that tie payment to patient outcomes. Consequently, commercial teams must prepare evidence dossiers that demonstrate clinical benefit and downstream cost offsets, and they must model scenarios that reflect potential supply chain cost pass-throughs. Strategic responses also include investment in manufacturing redundancy, selective onshoring of critical components, and closer collaboration with distributors and wholesalers to smooth logistical impacts on product availability.

Comprehensive segmentation analysis revealing how mechanism of action, clinical indication diversity, and end-user care settings define adoption pathways and commercial tactics

Key segmentation insights reveal how therapeutic mechanism, clinical indication, and points of care collectively shape adoption dynamics and commercial prioritization.

Based on mechanism of action, the therapeutic landscape spans inhaled corticosteroids (ICS), combined ICS/LABA regimens exemplified by fluticasone furoate vilanterol, triple-combination ICS/LAMA/LABA formulations such as fluticasone furoate umeclidinium vilanterol, as well as standalone bronchodilator classes that include LABA, LAMA with agents like umeclidinium, and dual LAMA/LABA combinations such as umeclidinium vilanterol. Within this structure, ICS/LABA combinations remain central for many patients due to their established anti-inflammatory and bronchodilatory synergy, while interest in triple therapies has risen for patients with persistent symptoms or frequent exacerbations, emphasizing the importance of comparative effectiveness data in shaping clinical decision-making.

Based on indication, the therapeutic focus spans asthma, asthma-COPD overlap presentations, and COPD as distinct clinical pathways with different therapeutic thresholds and monitoring priorities. Asthma management continues to emphasize stepwise escalation and de-escalation to balance control and safety, while COPD treatment paradigms tilt toward maximizing symptom control and minimizing exacerbation risk. Overlap phenotypes present additional complexity, requiring careful phenotyping and individualized therapy choices that often benefit from integrated care pathways and specialist input.

Based on end user, care delivery settings include homecare programs, hospitals, and specialty clinics, each with unique operational drivers. Homecare and outpatient management increasingly incorporate remote monitoring and patient education to support adherence and reduce acute visits, whereas hospitals and specialty clinics play a pivotal role in initiating advanced regimens, conducting inhaler technique training, and managing complex comorbidities. Consequently, commercial strategies that align clinician training, patient support, and distribution across these end-user settings strengthen uptake and optimize real-world therapeutic performance.

Regional strategies that align regulatory engagement, payer evidence generation, and supply chain resilience across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics materially influence regulatory strategy, reimbursement access, and clinical adoption across the Americas, Europe, Middle East & Africa, and Asia-Pacific.

In the Americas, regulatory pathways and payer models emphasize outcome evidence and cost-effectiveness, driving manufacturers to pair clinical data with health economic analyses and patient support initiatives. The United States market in particular demands robust real-world evidence and formulary engagement strategies that address heterogenous payer requirements, while Latin American markets often reflect variability in access and procurement approaches that can favor strategic partnerships with local distributors.

Across Europe, Middle East & Africa, regulatory harmonization in some regions coexists with distinct national reimbursement frameworks that shape launch sequencing and pricing. European health systems commonly require comparative effectiveness and budget impact information for formulary inclusion, and regional sustainability initiatives can influence device choice and procurement. Meanwhile, healthcare infrastructure heterogeneity across the Middle East and Africa necessitates tailored commercial and supply approaches that accommodate variability in care delivery and procurement capacity.

In the Asia-Pacific region, rapid healthcare modernization, expanding specialist networks, and growing emphasis on chronic disease management create both opportunities and complexities. Diverse regulatory environments, varying degrees of public reimbursement, and an expanding base of patients moving into treatment paradigms drive a need for regionally adapted evidence generation and distribution strategies. Manufacturers that invest in local evidence, clinician education, and supply chain robustness are better positioned to capitalize on adoption trends across these diverse geographies.

Competitive and commercial intelligence highlighting how lifecycle strategies, partnerships, digital adherence, and manufacturing resilience define company positioning

Competitive dynamics among established manufacturers and emerging players are reshaping product positioning, lifecycle strategies, and partnership models.

Incumbent companies with established inhaled therapies are focusing on lifecycle extensions through device refinement, label updates, and real-world evidence programs that emphasize safety and long-term outcomes. At the same time, competitors are differentiating through novel combinations, alternate delivery platforms, and investments in digital adherence technologies that pair pharmacology with patient behavior management. Partnerships and alliances-ranging from co-development agreements to commercialization collaborations-have become common mechanisms to accelerate access to complementary competencies such as device engineering, digital health integration, and regional distribution networks.

Supply chain strategies and manufacturing footprint decisions also distinguish competitive approaches. Firms that proactively diversify component sourcing, adopt modular manufacturing models, and invest in regional capacity can better navigate tariff fluctuations and logistic disruptions. Commercially, companies that align pricing, patient support, and outcome measurement are more effective in payer negotiations, while those that invest in clinician education and inhaler technique training strengthen prescribing confidence and long-term adherence. Overall, competitive success increasingly rests on integrating clinical differentiation with operational excellence and value-oriented commercial models.

Practical strategic actions for industry leaders to strengthen market access, ensure supply resilience, and increase patient adherence for inhaled therapeutic portfolios

Actionable recommendations provide a pragmatic blueprint for industry leaders seeking to strengthen positioning and accelerate sustainable uptake of inhaled therapies.

First, integrate robust real-world evidence programs into launch and lifecycle strategies to demonstrate clinical and economic value across diverse care settings. Complement randomized trial data with pragmatic studies and registries that capture adherence, exacerbation rates, and healthcare utilization to support payer discussions and clinician decision-making. Second, prioritize device ergonomics and patient training as central elements of product strategy; investments in inhaler design, instructional tools, and support programs materially improve technique and adherence, which in turn drive better outcomes.

Third, diversify manufacturing and sourcing to mitigate tariff and supply chain risks by establishing regional production hubs and securing alternative suppliers for critical components. Fourth, embrace digital health adjuncts that enable remote adherence monitoring and personalized interventions, and pair these technologies with outcomes-based contracting where feasible to align value creation with reimbursement. Finally, engage early with regulatory and payer stakeholders to align evidence generation plans with approval and reimbursement requirements, ensuring smoother market access pathways and more predictable commercial rollouts. Implementing these actions in concert will strengthen resilience, enhance patient outcomes, and create defensible commercial differentiation.

Description of the mixed-methods research approach combining clinician interviews, secondary literature synthesis, and multi-stage validation to produce robust insights

The research methodology blends primary qualitative inputs, systematic secondary review, and rigorous validation to ensure credible and actionable insights.

Primary research included structured interviews with clinical specialists in respiratory medicine, pharmacy directors, hospital procurement leads, and payers to capture frontline perspectives on prescribing behavior, formulary decision drivers, and operational constraints. Secondary review encompassed peer-reviewed clinical literature, regulatory filings, device performance studies, and public policy documents to contextualize clinical and commercial trends. Evidence synthesis prioritized high-quality sources and recent publications to reflect the current therapeutic environment.

All findings underwent multi-stage validation, including cross-referencing clinician interviews with secondary data and internal expert review to ensure consistency and minimize bias. Limitations were acknowledged where data variability existed across regions or where long-term outcomes data remained emergent. The methodology emphasizes transparency in assumptions and invites stakeholders to request deeper data appendices or tailored analyses that align with specific decision-making needs.

Concluding synthesis that ties together clinical trends, commercial imperatives, and operational priorities to inform strategic decision-making for inhaled therapies

In conclusion, the landscape for BREO Ellipta therapies and related inhaled combinations is shaped by clinical evolution, commercial pressures, and operational challenges that together define strategic priorities.

Clinical practice is moving toward more personalized regimens and greater use of combined therapies where appropriate, while digital tools and adherence programs are changing how long-term control is achieved and measured. Tariff changes and supply chain considerations reinforce the need for diversified sourcing and manufacturing agility, and regional differences in regulatory and payer environments require tailored evidence generation and market access plans. Competitive advantage will accrue to organizations that integrate clinical differentiation, device and digital support, and resilient operational models that together deliver demonstrable value to patients, providers, and payers.

Looking ahead, the successful commercialization of inhaled therapies will rely as much on execution across distribution, training, and value demonstration as it does on pharmacologic efficacy. Decision-makers should therefore align clinical development, market access, and operational strategies to capture sustainable uptake and ensure that patients receive consistent, effective respiratory care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Uptake of real-world effectiveness data supporting BREO Ellipta in reducing COPD exacerbations across diverse populations
  • 5.2. Shifting prescribing behavior towards BREO Ellipta as first-line maintenance therapy amid updated GINA asthma guidelines
  • 5.3. Market resistance from emerging biologic therapies targeting eosinophilic phenotypes impacting Ellipta prescription rates
  • 5.4. Pricing pressure from biosimilar inhaled corticosteroid combos challenging BREO Ellipta's market share growth
  • 5.5. Expansion of patient-assistance programs enhancing affordability and driving increased BREO Ellipta utilization among underinsured
  • 5.6. Digital inhaler add-ons integration improving adherence monitoring for BREO Ellipta patients in remote disease management
  • 5.7. Competitive positioning of triple therapy inhalers narrowing the market differentiation for BREO Ellipta in severe COPD

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. BREO Ellipta Drugs Market, by Mechanism Of Action

  • 8.1. ICS
  • 8.2. ICS/LABA
    • 8.2.1. Fluticasone Furoate Vilanterol
  • 8.3. ICS/LAMA/LABA
    • 8.3.1. Fluticasone Furoate Umeclidinium Vilanterol
  • 8.4. LABA
  • 8.5. LAMA
    • 8.5.1. Umeclidinium
  • 8.6. LAMA/LABA
    • 8.6.1. Umeclidinium Vilanterol

9. BREO Ellipta Drugs Market, by Indication

  • 9.1. Asthma
  • 9.2. Asthma COPD Overlap
  • 9.3. COPD

10. BREO Ellipta Drugs Market, by End User

  • 10.1. Homecare
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. BREO Ellipta Drugs Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. BREO Ellipta Drugs Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. BREO Ellipta Drugs Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. GlaxoSmithKline plc
    • 14.3.2. AstraZeneca plc
    • 14.3.3. Boehringer Ingelheim International GmbH
    • 14.3.4. Novartis AG
    • 14.3.5. Chiesi Farmaceutici S.p.A.
    • 14.3.6. Teva Pharmaceutical Industries Ltd
    • 14.3.7. Viatris Inc.
    • 14.3.8. Cipla Ltd
    • 14.3.9. Sun Pharmaceutical Industries Ltd
    • 14.3.10. Lupin Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BREO ELLIPTA DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. BREO ELLIPTA DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BREO ELLIPTA DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY FLUTICASONE FUROATE VILANTEROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY FLUTICASONE FUROATE VILANTEROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY FLUTICASONE FUROATE VILANTEROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY FLUTICASONE FUROATE VILANTEROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY FLUTICASONE FUROATE VILANTEROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY FLUTICASONE FUROATE VILANTEROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY FLUTICASONE FUROATE UMECLIDINIUM VILANTEROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY FLUTICASONE FUROATE UMECLIDINIUM VILANTEROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY FLUTICASONE FUROATE UMECLIDINIUM VILANTEROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY FLUTICASONE FUROATE UMECLIDINIUM VILANTEROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY FLUTICASONE FUROATE UMECLIDINIUM VILANTEROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY FLUTICASONE FUROATE UMECLIDINIUM VILANTEROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LABA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LABA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LABA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LABA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LABA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LABA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY UMECLIDINIUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY UMECLIDINIUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY UMECLIDINIUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY UMECLIDINIUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY UMECLIDINIUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY UMECLIDINIUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY UMECLIDINIUM VILANTEROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY UMECLIDINIUM VILANTEROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY UMECLIDINIUM VILANTEROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY UMECLIDINIUM VILANTEROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY UMECLIDINIUM VILANTEROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY UMECLIDINIUM VILANTEROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ASTHMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ASTHMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ASTHMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ASTHMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ASTHMA COPD OVERLAP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ASTHMA COPD OVERLAP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ASTHMA COPD OVERLAP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ASTHMA COPD OVERLAP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ASTHMA COPD OVERLAP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ASTHMA COPD OVERLAP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COPD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COPD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COPD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COPD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COPD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COPD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY HOMECARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, 2025-2032 (USD MILLION)
  • TABLE 123. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, 2025-2032 (USD MILLION)
  • TABLE 125. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, 2025-2032 (USD MILLION)
  • TABLE 127. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, 2025-2032 (USD MILLION)
  • TABLE 129. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 131. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. NORTH AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, 2018-2024 (USD MILLION)
  • TABLE 138. NORTH AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, 2025-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, 2018-2024 (USD MILLION)
  • TABLE 140. NORTH AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, 2025-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, 2018-2024 (USD MILLION)
  • TABLE 142. NORTH AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, 2025-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, 2018-2024 (USD MILLION)
  • TABLE 144. NORTH AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, 2025-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 146. NORTH AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. LATIN AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 152. LATIN AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, 2018-2024 (USD MILLION)
  • TABLE 154. LATIN AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, 2025-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, 2018-2024 (USD MILLION)
  • TABLE 156. LATIN AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, 2025-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, 2018-2024 (USD MILLION)
  • TABLE 158. LATIN AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, 2025-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, 2018-2024 (USD MILLION)
  • TABLE 160. LATIN AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. LATIN AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. MIDDLE EAST BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 200. MIDDLE EAST BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, 2018-2024 (USD MILLION)
  • TABLE 202. MIDDLE EAST BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 216. AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 227. AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, 2025-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, 2018-2024 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, 2025-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, 2025-2032 (USD MILLION)
  • TABLE 255. ASEAN BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, 2018-2024 (USD MILLION)
  • TABLE 256. ASEAN BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, 2025-2032 (USD MILLION)
  • TABLE 257. ASEAN BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, 2018-2024 (USD MILLION)
  • TABLE 258. ASEAN BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, 2025-2032 (USD MILLION)
  • TABLE 259. ASEAN BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 260. ASEAN BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 261. ASEAN BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. ASEAN BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. GCC BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GCC BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GCC BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 266. GCC BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 267. GCC BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, 2018-2024 (USD MILLION)
  • TABLE 268. GCC BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, 2025-2032 (USD MILLION)
  • TABLE 269. GCC BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, 2018-2024 (USD MILLION)
  • TABLE 270. GCC BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, 2025-2032 (USD MILLION)
  • TABLE 271. GCC BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, 2018-2024 (USD MILLION)
  • TABLE 272. GCC BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, 2025-2032 (USD MILLION)
  • TABLE 273. GCC BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, 2018-2024 (USD MILLION)
  • TABLE 274. GCC BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, 2025-2032 (USD MILLION)
  • TABLE 275. GCC BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 276. GCC BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 277. GCC BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. GCC BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPEAN UNION BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPEAN UNION BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPEAN UNION BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPEAN UNION BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPEAN UNION BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPEAN UNION BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPEAN UNION BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 295. BRICS BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. BRICS BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. BRICS BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 298. BRICS BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 299. BRICS BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, 2018-2024 (USD MILLION)
  • TABLE 300. BRICS BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, 2025-2032 (USD MILLION)
  • TABLE 301. BRICS BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, 2018-2024 (USD MILLION)
  • TABLE 302. BRICS BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, 2025-2032 (USD MILLION)
  • TABLE 303. BRICS BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, 2018-2024 (USD MILLION)
  • TABLE 304. BRICS BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, 2025-2032 (USD MILLION)
  • TABLE 305. BRICS BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, 2018-2024 (USD MILLION)
  • TABLE 306. BRICS BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, 2025-2032 (USD MILLION)
  • TABLE 307. BRICS BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 308. BRICS BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 309. BRICS BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 310. BRICS BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 311. G7 BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. G7 BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. G7 BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 314. G7 BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 315. G7 BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, 2018-2024 (USD MILLION)
  • TABLE 316. G7 BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, 2025-2032 (USD MILLION)
  • TABLE 317. G7 BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, 2018-2024 (USD MILLION)
  • TABLE 318. G7 BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, 2025-2032 (USD MILLION)
  • TABLE 319. G7 BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, 2018-2024 (USD MILLION)
  • TABLE 320. G7 BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, 2025-2032 (USD MILLION)
  • TABLE 321. G7 BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, 2018-2024 (USD MILLION)
  • TABLE 322. G7 BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, 2025-2032 (USD MILLION)
  • TABLE 323. G7 BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 324. G7 BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 325. G7 BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 326. G7 BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 327. NATO BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 328. NATO BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 329. NATO BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 330. NATO BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 331. NATO BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, 2018-2024 (USD MILLION)
  • TABLE 332. NATO BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, 2025-2032 (USD MILLION)
  • TABLE 333. NATO BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, 2018-2024 (USD MILLION)
  • TABLE 334. NATO BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LAMA/LABA, 2025-2032 (USD MILLION)
  • TABLE 335. NATO BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, 2018-2024 (USD MILLION)
  • TABLE 336. NATO BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, 2025-2032 (USD MILLION)
  • TABLE 337. NATO BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, 2018-2024 (USD MILLION)
  • TABLE 338. NATO BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA/LABA, 2025-2032 (USD MILLION)
  • TABLE 339. NATO BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 340. NATO BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 341. NATO BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 342. NATO BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 343. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 344. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 345. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 346. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 347. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, BY ICS/LABA, 2018-2024 (USD MILLION)

TABLE 348